Will Makary's FDA voucher program survive?

RevMed’s cancer drug feels out of reach for some, SCOTUS preserves key generic drug pathway, and more biotech news

Brendan SMIALOWSKI / AFP via Getty Images

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Even though RevMed’s experimental pancreatic cancer drug, daraxonrasib, hasn’t yet achieved approval, it is available through an expanded access program. But that doesn’t mean getting it is easy.

Also, the FDA’s voucher program spearheaded by erstwhile chief Marty Makary could be in for a makeover.